May 2019 TBC

Boston, USA

LinkedIn logo for website footerstwitter


Workshop A Workshop B

Pre-Conference Workshop Day

Tuesday May 22 2018, 9:00 am-12:00 pm


An In-depth Exploration of Treg Cell Heterogeneity

(This session is separately bookable)

09:00 am -12:00 pm  Workshop Leaders
This workshop explores the heterogeneity of Treg
cells which ensures that the immune responses are regulated and tolerance is maintained. Tregs are highly heterogeneous populations however the
understanding of the cellular and molecular pathways are limited. When Tregs lose their phenotype and suppressive functions they become pathogenic. Attend this workshop to improve your understanding on the significance of Treg heterogeneity in peripheral blood and tissues and explore their role in maintaining peripheral immune tolerance.Attendees will learn:

■ Outline the clinical landscape surrounding the
heterogeneity of Treg subsets

■ Explore tissue specific Treg cells and how to target specific subsets

Robert Plenge-1

Robert Plenge, Vice President of Research & Early Development, Head of Immunology & Inflammation,
Thematic Center of Excellence,  Celgene

Niranjana Nagarajan-1

Niranjana Nagarajan, Principal Scientist, Biotherapeutics, Celgene


Event Guide_Treg

Tuesday May 22 2018, 1:00 pm – 4:00 pm


New Approaches to Improving Cell Yield, Process Efficiency, and Therapeutic Potency in Clinical Regulatory T Cell Manufacturing Processes

(This session is separately bookable)

1:00 pm – 4:00 pm  Workshop Leader
Regulatory T cells (Tregs) are currently in clinical trials for a variety of indications, including graft versus host disease, autoimmune diseases, and induction of tolerance after solid organ transplant. A variety of new and old technologies and approaches are in active development to improve yields of Treg isolations, increase fold expansion, bring open processes into closed systems, target cells to specific tissues, and genetically modify cells to improve activity. Some of these approaches and technologies could lower cost for Treg manufacturing, which is critical to broader use of these therapies. Attend this manufacturing master class to gain an in-depth understanding of the current approaches and potential future breakthroughs in regulatory T cell manufacturing.
Attendees will learn:

■ Strategies for improving Treg yields at lower costs

■ Considerations for manufacturing processes and
release criteria to ensure safety

■ Current state of new technologies, including
synthetic biology approaches, which could improve Treg persistence and efficacy in vivo

Pierre Heimendinger, Vice President of Process Development, TxCell

Pierre has over 30 years of experience in biotechnology, immunotherapy, vaccines, plasma-derived medicinal products and viral vectors. Since he joined TxCell in late 2015, Pierre has been instrumental in developing TxCell’s first CAR-Treg manufacturing process. Before joining TxCell, Pierre held a senior position at Transgene SA where he led the pharmaceutical development team and was responsible for the development of new processes, analytical methods and technology transfer. He started his career at Sanofi Pasteur, then at Mérieux and Octapharma. Pierre has a doctor of pharmacy degree complemented by a postgraduate in cellular and genetic toxicology from the University of Paris VII.


Jonathan Esensten

Jonathan Esensten, Co-Director, Clinical Regulatory T Cell Manufacturing Group & Medical Director, UCSF HICTF & GMP Facility

Jonathan Esensten MD, PhD is a Leukemia and Lymphoma Society Fellow in the laboratory of Dr. Wendell Lim. His research is focused the development of synthetic and chemical biology approaches for T cell therapeutics. He is co-director of the clinical Regulatory T Cell Manufacturing Group. He is also Medical Director of the UCSF HICTF and GMP Facility, which manufactures regulatory T cell products for clinical trials, among other cell therapy activities. He completed residency in clinical pathology and fellowship in transfusion medicine and blood banking at UCSF.